rabbit anti arid1a polyclonal antibody  (Thermo Fisher)

Journal: Biomedical Reports

Article Title: Relationship between the protein expression of ARID1A, ARID1B and ARID2 with the clinicopathological characteristics of colorectal cancer

doi: 10.3892/br.2025.1997

Figure Lengend Snippet: Gene mutations, expression correlations and promoter methylation levels of ARID1A , ARID1B and ARID2 in COAD. (A) Genetic alterations of ARID1A , ARID1B and ARID2 in patients from TCGA-COAD cohort, analyzed using the Cancer Virtual Cohort Discovery Analysis Platform. Expression correlations between (B) ARID1A and ARID1B , (C) ARID1A and ARID2 and (D) ARID1B and ARID2 in TCGA-COAD cohort, analyzed via the Gene Expression Profiling Interactive Analysis 2 platform. The promoter methylation level of (E) ARID1A , (F) ARID1B and (G) ARID2 in TCGA-COAD samples, analyzed via The University of ALabama at Birmingham CANcer data analysis portal. ** P<0.01. ARID, AT-rich interactive domain; COAD, colon adenocarcinoma; TCGA, The Cancer Genome Atlas.

Article Snippet: To assess the expression of the ARID proteins, IHC was performed using the following specific antibodies: Anti-ARID1A rabbit polyclonal antibody (1:400; cat. no. HPA005456; MilliporeSigma), anti-ARID1B mouse monoclonal antibody (1:200; cat. no. ab57461; Abcam) and anti-ARID2 rabbit polyclonal antibody (1:250; cat. no. ab113283; Abcam).

Techniques: Expressing, Methylation, Gene Expression

Journal: Biomedical Reports

Article Title: Relationship between the protein expression of ARID1A, ARID1B and ARID2 with the clinicopathological characteristics of colorectal cancer

doi: 10.3892/br.2025.1997

Figure Lengend Snippet: ARID1A, ARID1B and ARID2 protein expression in colorectal cancer tissues. Immunohistochemistry of (A) ARID1A, (B) ARID1B and (C) ARID2 proteins in the adjacent non-cancerous area compared with the cancerous area. ARID protein staining appears brown (magnification, x400; scale bar, 20 µm). The H-score of (D) ARID1A, (E) ARID1B and (F) ARID2 protein expression in the non-cancerous area (black bar) compared with the cancerous area (white bar). The data are presented as the mean ± SEM and analyzed by the Mann-Whitney U test. (G) Distribution of ARID1A, ARID1B and ARID2 expression categorization in adjacent non-cancerous and cancerous areas. Expression is classified as low or high depending on the median H-score. ARID1A cut-off, 164; ARID1B cut-off, 100; ARID2 cut-off, 78. * P<0.05, ** P<0.01 and *** P<0.001. ARID, AT-rich interactive domain; H-score, histoscore; SEM, standard error of the mean; NA, adjacent non-cancerous area; CA, cancerous area.

Article Snippet: To assess the expression of the ARID proteins, IHC was performed using the following specific antibodies: Anti-ARID1A rabbit polyclonal antibody (1:400; cat. no. HPA005456; MilliporeSigma), anti-ARID1B mouse monoclonal antibody (1:200; cat. no. ab57461; Abcam) and anti-ARID2 rabbit polyclonal antibody (1:250; cat. no. ab113283; Abcam).

Techniques: Expressing, Immunohistochemistry, Staining, MANN-WHITNEY

Journal: Biomedical Reports

Article Title: Relationship between the protein expression of ARID1A, ARID1B and ARID2 with the clinicopathological characteristics of colorectal cancer

doi: 10.3892/br.2025.1997

Figure Lengend Snippet: Expression correlations of ARID1A, ARID1B and ARID2 protein in colorectal cancer. Scatterplots showing the relationships between (A) ARID1A and ARID1B, (B) ARID1A and ARID2 and (C) ARID1B and ARID2. (D) Heatmap of Spearman's correlation coefficients among the ARID proteins. * P<0.05. ARID, AT-rich interactive domain; H-score, histoscore.

Article Snippet: To assess the expression of the ARID proteins, IHC was performed using the following specific antibodies: Anti-ARID1A rabbit polyclonal antibody (1:400; cat. no. HPA005456; MilliporeSigma), anti-ARID1B mouse monoclonal antibody (1:200; cat. no. ab57461; Abcam) and anti-ARID2 rabbit polyclonal antibody (1:250; cat. no. ab113283; Abcam).

Techniques: Expressing

Journal: Biomedical Reports

Article Title: Relationship between the protein expression of ARID1A, ARID1B and ARID2 with the clinicopathological characteristics of colorectal cancer

doi: 10.3892/br.2025.1997

Figure Lengend Snippet: Relationship between ARID1A, ARID1B and ARID2 protein expression and the survival outcomes of patients with CRC. The 5-year progression-free survival outcomes based on the expression status of (A) ARID1A, (B) ARID1B and (C) ARID2 in patients with CRC (n=63), analyzed using log-rank test. Overall survival based on the expression status of (D) ARID1A, (E) ARID1B and (F) ARID2 in patients with CRC, analyzed using the KM plotter database. The KM plots for overall survival were generated directly by the KM plotter tool without any additional statistical analysis or modification. A late-stage crossover was observed in the survival curves, as provided by the tool. * P<0.05. ARID, AT-rich interactive domain; CRC, colorectal cancer; KM, Kaplan-Meier.

Article Snippet: To assess the expression of the ARID proteins, IHC was performed using the following specific antibodies: Anti-ARID1A rabbit polyclonal antibody (1:400; cat. no. HPA005456; MilliporeSigma), anti-ARID1B mouse monoclonal antibody (1:200; cat. no. ab57461; Abcam) and anti-ARID2 rabbit polyclonal antibody (1:250; cat. no. ab113283; Abcam).

Techniques: Expressing, Generated, Modification

Journal: Oncology Letters

Article Title: Proteomic insights into the regulatory function of ARID1A in colon cancer cells

doi: 10.3892/ol.2024.14525

Figure Lengend Snippet: ARID1A protein expression in the empty vector control and ARID1A-overexpressing cells. (A) Western blot images of ARID1A and GAPDH (loading control). (B) Band intensity of ARID1A relative to GAPDH. The bar graph represents the mean ± standard deviation (n=3 per group). *P<0.05. ARID1A, AT-rich interacting domain-containing protein 1A; O/E, overexpression; MW, molecular weight.

Article Snippet: The membrane was incubated with 5% skimmed milk in PBS at 25°C for 1 h. Subsequently, it was incubated with rabbit polyclonal anti-ARID1A (1:1,000; cat. no. HPA005456; Sigma-Aldrich; Merck KGaA), rabbit monoclonal anti-c-Myc (1:1,000; cat. no. 5605; Cell Signaling Technology, Inc.), rabbit monoclonal anti-T cell factor (TCF)1/7 (1:1,000; cat. no. 2203; Cell Signaling Technology, Inc.), rabbit monoclonal anti-cyclin D1 (1:1,000; cat. no. 2978; Cell Signaling Technology, Inc.), rabbit polyclonal anti-zinc and ring finger 3 (ZNRF3; 1:1,000; cat. no. DF14289; Affinity Biosciences), or mouse monoclonal anti-GAPDH (1:5,000; cat. no. ab8245; Abcam) antibodies at 4°C overnight.

Techniques: Expressing, Plasmid Preparation, Control, Western Blot, Standard Deviation, Over Expression, Molecular Weight

Journal: Oncology Letters

Article Title: Proteomic insights into the regulatory function of ARID1A in colon cancer cells

doi: 10.3892/ol.2024.14525

Figure Lengend Snippet: Involvement of ARID1A and altered proteins in the Wnt signaling pathway. (A) Wnt signaling pathway information generated using Kyoto Encyclopedia of Genes and Genomes (hsa04310). The pathway is illustrated using data from the KEGG database ( https://www.genome.jp/pathway/hsa04310 ) . Red boxes indicate differentially altered proteins. (B) Western blot images for c-Myc, TCF1/TCF7 and cyclin D1, with GAPDH as the loading control. (C) Band intensity of proteins relative to GAPDH. The bar graph represents the mean ± standard deviation (n=3 per group). *P<0.05. ARID1A, AT-rich interacting domain-containing protein 1A; TCF, T cell factor; O/E, overexpression; MW, molecular weight.

Article Snippet: The membrane was incubated with 5% skimmed milk in PBS at 25°C for 1 h. Subsequently, it was incubated with rabbit polyclonal anti-ARID1A (1:1,000; cat. no. HPA005456; Sigma-Aldrich; Merck KGaA), rabbit monoclonal anti-c-Myc (1:1,000; cat. no. 5605; Cell Signaling Technology, Inc.), rabbit monoclonal anti-T cell factor (TCF)1/7 (1:1,000; cat. no. 2203; Cell Signaling Technology, Inc.), rabbit monoclonal anti-cyclin D1 (1:1,000; cat. no. 2978; Cell Signaling Technology, Inc.), rabbit polyclonal anti-zinc and ring finger 3 (ZNRF3; 1:1,000; cat. no. DF14289; Affinity Biosciences), or mouse monoclonal anti-GAPDH (1:5,000; cat. no. ab8245; Abcam) antibodies at 4°C overnight.

Techniques: Generated, Western Blot, Control, Standard Deviation, Over Expression, Molecular Weight

Journal: Oncology Letters

Article Title: Proteomic insights into the regulatory function of ARID1A in colon cancer cells

doi: 10.3892/ol.2024.14525

Figure Lengend Snippet: Association between ARID1A and altered proteins involved in the Wnt signaling pathway. (A) Interaction network of ARID1A and altered proteins involved in the Wnt signaling pathway constructed using GeneMANIA. (B) Heatmap of the HR of TCF7L1 and ZNRF3 for the overall survival of patients with COAD, created using GEPIA2. The framed block indicates a significant prognostic value. (C) Kaplan-Meier curve for overall survival of patients with COAD with different levels of ZNRF3 expression, plotted using GEPIA2. (D) Correlation between the expression of ARID1A and ZNRF3 in COAD, analyzed using GEPIA2. ARID1A, AT-rich interacting domain-containing protein 1A; TCF7L1, transcription factor 7 like 1; ZNRF3, zinc and ring finger 3; COAD, colon adenocarcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; HR, hazard ratio; TPM, transcripts per million.

Article Snippet: The membrane was incubated with 5% skimmed milk in PBS at 25°C for 1 h. Subsequently, it was incubated with rabbit polyclonal anti-ARID1A (1:1,000; cat. no. HPA005456; Sigma-Aldrich; Merck KGaA), rabbit monoclonal anti-c-Myc (1:1,000; cat. no. 5605; Cell Signaling Technology, Inc.), rabbit monoclonal anti-T cell factor (TCF)1/7 (1:1,000; cat. no. 2203; Cell Signaling Technology, Inc.), rabbit monoclonal anti-cyclin D1 (1:1,000; cat. no. 2978; Cell Signaling Technology, Inc.), rabbit polyclonal anti-zinc and ring finger 3 (ZNRF3; 1:1,000; cat. no. DF14289; Affinity Biosciences), or mouse monoclonal anti-GAPDH (1:5,000; cat. no. ab8245; Abcam) antibodies at 4°C overnight.

Techniques: Construct, Blocking Assay, Expressing

Journal: Oncology Letters

Article Title: Proteomic insights into the regulatory function of ARID1A in colon cancer cells

doi: 10.3892/ol.2024.14525

Figure Lengend Snippet: ZNRF3 protein expression in the empty vector control and ARID1A-overexpressing cells. (A) Western blot images of ZNRF3 and GAPDH (loading control) expression. (B) Band intensity of ZNRF3 expression relative to GAPDH. The bar graph represents the mean ± standard deviation (n=3 per group). *P<0.05. ZNRF3, zinc and ring finger 3; ARID1A, AT-rich interacting domain-containing protein 1A; O/E, overexpression; MW, molecular weight.

Article Snippet: The membrane was incubated with 5% skimmed milk in PBS at 25°C for 1 h. Subsequently, it was incubated with rabbit polyclonal anti-ARID1A (1:1,000; cat. no. HPA005456; Sigma-Aldrich; Merck KGaA), rabbit monoclonal anti-c-Myc (1:1,000; cat. no. 5605; Cell Signaling Technology, Inc.), rabbit monoclonal anti-T cell factor (TCF)1/7 (1:1,000; cat. no. 2203; Cell Signaling Technology, Inc.), rabbit monoclonal anti-cyclin D1 (1:1,000; cat. no. 2978; Cell Signaling Technology, Inc.), rabbit polyclonal anti-zinc and ring finger 3 (ZNRF3; 1:1,000; cat. no. DF14289; Affinity Biosciences), or mouse monoclonal anti-GAPDH (1:5,000; cat. no. ab8245; Abcam) antibodies at 4°C overnight.

Techniques: Expressing, Plasmid Preparation, Control, Western Blot, Standard Deviation, Over Expression, Molecular Weight

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: Primer lists and their sequences used in the study

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Sequencing, Negative Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: Identified differentially expressed genes (DEGs)in HCT116‐ARID1A‐wild‐type vs. HCT116‐ARID1A‐knockout (A) Volcano plot of differentially expressed genes (B) Heat map of DEGs in control and knockout groups (C) upper part,KEGG and GO enrichment analysis of differentially upregulated genes. (C) lower part ,KEGG and GO enrichment analysis of differentially downregulated genes

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Knock-Out, Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: Expression of EMT‐related markers (VIM) and correlation with ARID1A (A) Vimentin (VIM) overexpression was found in KO cell lines (B) VIM high expression is associated with a poor prognosis in COAD (C) VIM displays high expression in cells with lower ARID1A expression (SW620&RKO) and low expression in cells with a high ARID1A expression (HCT116&LoVo) (D) colon cancer samples were examined for co‐expression of Vimentin and ARID1A (E) GEPIA2 database visualization of the co‐expression of Vimentin and ARID1A in colon cancer tissue.

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Expressing, Over Expression

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: Expression of EMT‐related marker (CDH1) and correlation with ARID1A (A) CDH1 is downregulated in ARID1A deficient cells (B) shows a Kaplan–Maier result of CDH1 in COAD (C and D) E‐cadherin expression correlates positively with ARID1A expression in COAD

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Expressing, Marker

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: ARID1A sequence and mutation profiles in CRC cells used in the research

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Sequencing, Mutagenesis, Variant Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: ARID1A knockdown in HCT116 cell line (A) At 50 nM, 4 μl siRNA‐ARID1A, qPCR demonstrates no change of vimentin and E‐cadherin expression levels in HCT116 after 24 h transfection (B) ARID1A deficiency at 75 nM, 6 μl siRNA‐ARID1A for 24 h activates VIM and suppress CDH1 in HCT116 (C) qPCR results of ARID1A downregulation using 75 nM, 6‐μl siRNA for 48 h showed VIM and CDH1 expression in HCT116. ARID1A silencing altered VIM and E‐cadherin expression (D and E) VIM and CDH1 expression were altered in qPCR results of LS174‐T‐ARID1A knocked down for 24 and 48 h, respectively. ns, Non‐significant; *p < 0.05, **p < 0.001, and ***p < 0.0001

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Knockdown, Expressing, Transfection

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: ARID1A silencing alters VIM and E‐cadherin expression (A and B) VIM and CDH1 expression were altered in WB results after ARID1A knocked down for 24 and 48 h.

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Expressing

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: ARID1A knockdown promotes colon cell line migration and proliferation (A and B) The effect of ARID1A depletion on HCT116 and LS174T cell migration (C) The effect of ARID1A depletion on LS174T cell invasion (D) The proliferation of HCT116 cells was assessed at specified times following ARID1A siRNA transfection (E) Immunoprecipitated DNA from ChIP experiments with anti‐ARID1A antibody was examined by real‐time qPCR using E‐cadherin and Vimentin‐specific promoter primers. IP stands for Immunoprecipitated. *p < 0.05, **p < 0.001, and ***p < 0.0001. Statistical differences were calculated using an imageJ software.

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: Knockdown, Migration, Transfection, Immunoprecipitation, Software

Journal: Journal of Cellular and Molecular Medicine

Article Title: ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression

doi: 10.1111/jcmm.17590

Figure Lengend Snippet: List of 87 ARID1A interaction proteins in HCT116

Article Snippet: The membrane was incubated overnight at 4°C with rabbit antibodies against β‐actin (1:1000, Beijing Zhongshan Biotechnology Co., Ltd); ARID1A (1:300, CUSABIO TECHNOLOGY LLC); E‐cadherin Polyclonal antibody, cat on: 20874‐1‐AP; and Vimentin Polyclonal antibody, cat no: 10366‐1‐AP after blocking with 5% non‐fat milk in Tris‐buffered saline containing 0.05%Tween‐20 (1–1000).

Techniques: